Trial Profile
A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jan 2019
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms ENHANCE
- Sponsors Biogen
- 10 Dec 2018 Results published in the CNS Drugs
- 12 Oct 2018 Results evaluating the effect of PR-Fampridine on patient reported hand function using the 23 item ABILHAND presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results of post hoc integrated efficacy analysis of prolonged-release fampridinevs placebo using MOBILE and ENHANCE data presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis